Cardiff Oncology, Inc. Logo

Cardiff Oncology, Inc.

A clinical-stage biotech developing cancer therapies that inhibit Polo-like kinase 1.

CRDF | US

Overview

Corporate Details

ISIN(s):
US14147L1089
LEI:
Country:
United States of America
Address:
11055 FLINTKOTE AVENUE, 92121 SAN DIEGO

Description

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-06 17:08
8-K
English ZIP 114.3 KB
2025-11-06 17:00
10-Q
English ZIP 1.0 MB
2025-08-28 18:56
S-8
English ZIP 460.8 KB
2025-08-14 19:06 English ZIP 10.1 KB
2025-07-31 18:05
4
English ZIP 6.7 KB
2025-07-29 18:10
8-K
English ZIP 29.4 MB
2025-07-29 18:00
10-Q
English ZIP 1010.8 KB
2025-07-29 13:26 English ZIP 8.3 KB
2025-07-08 18:05
3
English ZIP 6.0 KB
2025-06-30 11:39 English ZIP 6.9 KB
2025-06-30 11:38 English ZIP 7.0 KB
2025-06-30 11:38 English ZIP 6.9 KB
2025-06-27 22:45 English ZIP 5.2 KB
2025-06-27 21:40 English ZIP 4.2 KB
2025-06-27 21:38 English ZIP 6.9 KB

Automate Your Workflow. Get a real-time feed of all Cardiff Oncology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cardiff Oncology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cardiff Oncology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.